longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Corcept Therap

CORT

110.2903.98% ( -4.570 )
Closed: Sep 18, 15:59:52 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 228.79, above the reasonable range, cheaper than 0.92% of the time in the past 5 years, and the industry ranks 60/257, the industry Median -1.30.

228.79xP/E
$114.86Stock price
$0.50Earnings per share
228.79xP/E
Stock price$114.86Earnings per share$0.50

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
28.86x
Typical range
22.99x–55.63x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
058116174232

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
MRKUSMerck
114.42x81.12%$363.04B
CORTUSCorcept Therap
228.79x151.22%$12.42B
HCMUSHutchmed China
134.83x90.11%$2.41B
ETONUSEton Pharmaceuticals
128.57x739.71%$1.63B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.